Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (22)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by de Jong, N.
Right arrow Articles by Courtens, A. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by de Jong, N.
Right arrow Articles by Courtens, A. M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 15:896-905, 2004
© 2004 European Society for Medical Oncology

Original Paper

Prevalence and course of fatigue in breast cancer patients receiving adjuvant chemotherapy

Received 29 October 2003; revised 10 February 2004; accepted 11 February 2004

Background:

The purpose of this study was to determine the prevalence of fatigue and the course of fatigue as a function of chemotherapy in breast cancer patients undergoing adjuvant chemotherapy.

Patients and methods:

In a prospective cohort study, a sample of 157 patients with breast cancer were interviewed, using the Rotterdam Symptom Checklist and the Multidimensional Fatigue Inventory, at the first, third and fifth cycle of adjuvant chemotherapy, as well as 4 and 12 weeks after the last cycle of adjuvant chemotherapy. Patients were treated with either a doxorubicin-containing schedule, or cyclophosphamide, methotrexate and 5-fluorouracil (CMF).

Results:

The courses of general and physical fatigue are to a large extent similar. After the last cycle of chemotherapy, the CMF group reported a significant increase in fatigue, which was followed by a significant reduction. In the doxorubicin group a significant increase in fatigue was only seen during the first cycles of chemotherapy. The fatigue experienced at the first and the last measurements do not differ significantly.

Conclusions:

The prevalence of fatigue increased significantly after the start of chemotherapy. After chemotherapy treatment the prevalence rate seemed to decline. A different impact of chemotherapy on the course of fatigue was found. In the doxorubicin group a direct increase in fatigue was found. In the CMF group a moderate direct increase occurred, followed by a delayed strong increase. An increase in fatigue was associated with a decrease in daily functioning. At all measurement occasions fatigue was affected by type of operation, such that women with a mastectomy were more fatigued than women that underwent a lumpectomy. Receiving radiotherapy also led to an increase in fatigue. With this knowledge breast cancer patients can be better informed about what they can expect. Further research should include interventions addressing how to reduce or cope with fatigue during as well as after receiving adjuvant chemotherapy.

N. de Jong1,*, M. J. J. M. Candel2, H. C. Schouten3, H. Huijer Abu-Saad1,4 and A. M. Courtens1

Departments of 1 Health Care Studies and 2 Methodology and Statistics, Universiteit Maastricht, Maastricht; 3 Department of Internal Medicine, University Hospital Maastricht, Maastricht, The Netherlands; 4 School of Nursing and Faculty of Medicine, American University of Beirut, Beirut, Lebanon

Key words: adjuvant chemotherapy, breast cancer, fatigue


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Research on Social Work PracticeHome page
M. Cohen and G. Fried
Comparing Relaxation Training and Cognitive-Behavioral Group Therapy for Women With Breast Cancer
Research on Social Work Practice, May 1, 2007; 17(3): 313 - 323.
[Abstract] [PDF]

Home page
 The OncologistHome page
P. Jean-Pierre, C. D. Figueroa-Moseley, S. Kohli, K. Fiscella, O. G. Palesh, and G. R. Morrow
Assessment of Cancer-Related Fatigue: Implications for Clinical Diagnosis and Treatment
Oncologist, May 1, 2007; 12(suppl_1): 11 - 21.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
H. G. M. Fan, N. Houede-Tchen, Q.-L. Yi, I. Chemerynsky, F. P. Downie, K. Sabate, and I. F. Tannock
Fatigue, Menopausal Symptoms, and Cognitive Function in Women After Adjuvant Chemotherapy for Breast Cancer: 1- and 2-Year Follow-Up of a Prospective Controlled Study
J. Clin. Oncol., November 1, 2005; 23(31): 8025 - 8032.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
N. de Jong, M. J. J. M. Candel, H. C. Schouten, H. Huijer Abu-Saad, and A. M. Courtens
Course of mental fatigue and motivation in breast cancer patients receiving adjuvant chemotherapy
Ann. Onc., March 1, 2005; 16(3): 372 - 382.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.